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ABSTRACT
Objective To characterise whether some selective
serotonin reuptake inhibitor (SSRI) antidepressants
reduce tamoxifen’s effectiveness by inhibiting its
bioactivation by cytochrome P450 2D6 (CYP2D6).
Design Population based cohort study.
Participants Women living in Ontario aged 66 years or
older treated with tamoxifen for breast cancer between
1993 and 2005 who had overlapping treatment with a
single SSRI.
MainoutcomemeasuresRiskofdeathfrombreastcancer
after completion of tamoxifen treatment, as a function of
the proportion of time on tamoxifen during which each
SSRI had been co-prescribed.
Results Of 2430 women treated with tamoxifen and a
single SSRI, 374 (15.4%) died of breast cancer during
follow-up (mean follow-up 2.38 years, SD 2.59). After
adjustment for age, duration of tamoxifen treatment, and
other potential confounders, absolute increases of 25%,
50%,and75%intheproportionoftimeontamoxifenwith
overlapping use of paroxetine (an irreversible inhibitor of
CYP2D6) were associated with 24%, 54%, and 91%
increases in the risk of death from breast cancer,
respectively(P<0.05foreachcomparison).Bycontrast,no
such risk was seen with other antidepressants. We
estimate that use of paroxetine for 41% of tamoxifen
treatment (the median overlap in our sample) would
result in one additional breast cancer death within five
years of cessation of tamoxifen for every 19.7 (95%
confidence interval 12.5 to 46.3) patients so treated; the
risk with more extensive overlap would be greater.
Conclusion Paroxetine use during tamoxifen treatment is
associated with an increased risk of death from breast
cancer, supporting the hypothesis that paroxetine can
reduce or abolish the benefit of tamoxifen in women with
breast cancer.
INTRODUCTION
Breast cancer is the most commonly diagnosed cancer
in women worldwide, and it is estimated that 1.5 mil-
lionnewcaseswillbediagnosedin2010.
1Tamoxifenis
aselectiveoestrogenreceptormodulatorthathasbeen
used for the treatment of breast cancer for over three
decades.
2 In women with early stage oestrogen recep-
torpositivebreastcancer,tamoxifenreducestheriskof
recurrence by about half and the risk of breast cancer
death by abouta third. Thesebenefitsare largely inde-
pendent of chemotherapy, age, progesterone receptor
status, or other tumour characteristics.
3
Tamoxifen is a prodrug that is metabolised by the
hepatic cytochrome P450 enzyme system to the active
metabolites 4-hydroxytamoxifen and 4-hydroxy-N-
desmethyltamoxifen (endoxifen).
45 Both metabolites
have an affinity for the oestrogen receptor that is 100-
foldhigherthantheparentcompound;however,endo-
xifen is considered the most important metabolite
because its plasma concentrations are several times
higher than those of 4-hydroxytamoxifen.
67 Conver-
sion of tamoxifen to endoxifen is catalysed predomi-
nantly by cytochrome P450 isoenzyme 2D6
(CYP2D6).
47 This enzyme is highly polymorphic,
8
and in some studies loss-of-function variants are asso-
ciated with lower endoxifen concentrations,
5 an
increased risk of breast cancer relapse and a shorter
time to recurrence during tamoxifen therapy.
9-14 Con-
sequently, therapy with drugs that inhibit CYP2D6
may reduce the clinical benefit of tamoxifen by inter-
fering with its bioactivation, particularly when these
drugs are used for an extended period. Indeed, in
patients who receive tamoxifen in combination with a
CYP2D6 inhibitor, endoxifen concentrations vary
inversely with the degree of CYP2D6 inhibition.
51516
Up to 25% of patients with breast cancer experience
a depressive disorder.
17 Newer antidepressants are
widelyusedinwomenwithbreastcancerfortreatment
of depression and are prescribed for tamoxifen related
hotflashesandvariousotherindications.
18-21Thisprac-
tice is particularly relevant in the context of tamoxifen
therapy because selective serotonin reuptake inhibitor
(SSRI) antidepressants inhibit CYP2D6 to varying
degrees. For example, paroxetine is an exceptionally
potent CYP2D6 inhibitor, and is the only SSRI that
exhibits mechanism based (“suicide”) inhibition,
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new CYP2D6 is synthesised.
22-24
Whether antidepressant related inhibition of
CYP2D6 is associated with adverse outcomes in
patients receiving tamoxifen is unknown. To explore
this possibility, we linked prescribing records with
detailed clinical data from a large population based
cancer registry and other population based healthcare
datasets to explore the clinical consequences of the
potential interaction between SSRIs and tamoxifen.
METHODS
Setting and design
We did a population based retrospective cohort study
amongfemaleresidentsofOntario,Canada,whowere
aged66yearsorolderandwhostartedtamoxifentreat-
mentbetween1January1993and31 December2005.
These individuals have universal access to health care,
includinghospitalcare,doctor’sservices,andprescrip-
tion drug coverage. The study was approved by the
research ethics board of Sunnybrook Health Sciences
Centre, Toronto, Canada.
Data sources
We analysed the computerised prescription records of
the Ontario Public Drug Benefit Program, which con-
tainscomprehensiverecordsofprescriptionmedications
dispensed to all Ontario residents aged 65 or older. We
identified women with breast cancer using the Ontario
Cancer Registry, a population based tumour registry
that contains pathology reports, hospital discharge
abstracts, and death certificates of patients with a diagno-
sis of cancer. Hospital admissions were identified using
theCanadianInstituteforHealthInformationDischarge
Abstract database, which contains information on hospi-
tal visits, including detailed clinical and demographic
informationonallhospitaladmissions. Doctors’services
were identified using the Ontario Health Insurance Plan
database, and we obtained basic demographic informa-
tion,includingdateofdeath,fromtheRegisteredPersons
database. We estimated socioeconomic status by linking
residentialpostalcodeswithStatisticsCanadapopulation
census data. These datasets were linked using an
encrypted version of each patient’s1 0d i g i th e a l t hc a r d
number to ensure anonymity, and they are regularly
used to study drug safety, including the clinical conse-
quences of drug interactions.
25-30
Design and analysis
We identified a cohort of women starting tamoxifen
treatment, beginning with the first tamoxifen prescrip-
tion after each patient’s 66th birthday. All patients
were newly treated with tamoxifen (defined as no
tamoxifen prescription in the preceding year), and
had a diagnosis of breast cancer in the Ontario Cancer
Registry (International Classification of Disease ver-
sion 9 (ICD-9) codes 174.0-174.9). We did not include
patientsduringtheirfirstyearofeligibilityforprescrip-
tion drug coverage (age 65) to avoid incomplete med-
ication records.
Foreachpatient,wedeterminedthetotaldurationof
tamoxifentreatmentbyaggregatingthetotaldayssup-
pliedforalltamoxifenprescriptions.Werestrictedour
analysis to women whose tamoxifen use encompassed
at least 80% of the total number of days between the
first and last tamoxifen prescriptions. In addition, we
restrictedouranalysistowomenco-prescribedasingle
SSRI antidepressant (paroxetine, fluoxetine, sertra-
line, citalopram, or fluvoxamine) during tamoxifen
treatment. We also included venlafaxine, which inhi-
bitsserotoninreuptakeaswellasnorepinephrinereup-
take at higher doses.
31 We did not study duloxetine or
escitaloprambecausetheywerenotinsuredbenefitsof
the provincial formulary during the study period.
Foranalyticalpurposes,wedefinedtheindexdateas
thedateonwhichtamoxifenwaslastdispensed,plusan
additional 60 days. This allowed us to completely
ascertain the total duration of tamoxifen treatment
and the extent to which co-prescription of potentially
interacting medications occurred during the course of
treatment.Moreover,it allowedusto adequately char-
acterise the mortality consequences of the drug inter-
action between SSRIs and tamoxifen, which are
delayed and largely occur after the completion of
tamoxifen treatment, in contrast with most other clini-
cally important drug interactions, which usually have
more immediate clinical consequences.
293032
In the primary analysis, patients were followed up
from the index date until death from breast cancer or
the end of the study period (31 December 2007),
whicheveroccurredfirst.Asecondaryanalysisconsid-
ered death from any cause, including breast cancer.
For each patient, we quantified the duration of tamox-
ifen treatment and the proportion of this time that was
characterised by concomitant SSRI treatment.
Because we expected that the consequences of
CYP2D6 inhibition during tamoxifen therapy would
be delayed, we excluded women who switched from
one SSRI to another while taking tamoxifen. Conse-
quently, all women in our analysis were 66 years or
older, newly treated with tamoxifen for breast cancer,
and treated with a single SSRI antidepressant during
tamoxifen treatment.
The primary outcome was death from breast cancer
(ICD9codes174.0to174.9andICD10codesC50.0to
50.9).WeusedCoxproportionalhazardsregressionto
examine the effect of SSRI co-prescribing on survival
following cessation of tamoxifen. In each analysis, we
expressed exposure as the proportion of time on
tamoxifen that was characterised by overlapping
SSRI treatment.
For each SSRI, we estimated hazard ratios and 95%
confidence intervals associated with increasing pro-
portions of co-prescribing of that same drug with
tamoxifen, thereby restricting our analyses to within-
drug comparisons. Consequently, the analysis
explored the relation between a continuous measure
(proportion of overlapbetweeneach SSRI and tamox-
ifen)andbreastcancermortality,withouttheneedfora
reference group. The regression model was adjusted
for age, year that tamoxifen was started, duration of
RESEARCH
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dateofbreastcancerdiagnosis(withinoneyearofdiag-
nosisorthereafter),socioeconomicstatus,comorbidity
in the year before completion of tamoxifen
treatment,
33 and co-prescription of other CYP2D6
inhibitors (bupropion, quinidine, thioridazine, amio-
darone, cimetidine, or chloroquine) during tamoxifen
treatment. The proportional hazards assumption was
verified using Schoenfeld residuals.
34 All analyses
were done with SAS version 9.1 (SAS Institute,
Cary N.C.) and used a two-tailed type 1 error rate of
0.05 as the threshold for statistical significance.
RESULTS
We identified 24430 women aged 66 years and older
who started tamoxifen treatment during the 13 year
study period (appendix 1). Of these, 7489 (30.6%)
received at least one antidepressant during tamoxifen
treatment. After excluding those treated with no SSRI
or with multiple SSRIs, those with poor adherence to
tamoxifen,andthosewithunknowncauseofdeath,the
primary analysis included 2430 women (table 1). The
median age in the year before starting tamoxifen was
74 years (interquartile range (IQR) 70-79).
Most patients (n=2025; 83.3%) started tamoxifen
treatment within one year of breast cancer diagnosis.
The median duration of tamoxifen treatment was 4.
0 years (IQR 2.2-5.0), ranging from 3.2 years (1.4-4.8)
in women who also received fluoxetine to 4.2 years
(2.5-5.1) among women who also received citalopram
(appendix 2). Paroxetine was the most commonly pre-
scribed SSRI (n=630; 25.9%) followed by sertraline
(n=541; 22.3%), citalopram (n=467; 19.2%), venlafax-
ine (n=365; 15.0%) fluoxetine (n=253; 10.4%) and flu-
voxamine(n=174;7.2%).Overall,735patients(30.2%)
received at least one other non-SSRI antidepressant,
including 445 (18.3%) who received a cyclic anti-
depressant, 209 (8.6%) who received other anti-
depressants, and 81 (3.3%) who received both. The
distribution of these patients was relatively similar
across the various SSRI groups (appendix 3).
Main analyses
Intotal,1074women(44.2%)diedbytheendoffollow-
up(meanfollow-up2.38years,SD2.59),including374
(15.4%) in whom breast cancer was recorded as the
cause of death. In the primary analysis, we found an
increased risk of death from breast cancer among
women who received paroxetine, an irreversible
CYP2D6 inhibitor, in combination with tamoxifen.
After adjusting for potential confounders, absolute
increases of 25%, 50%, and 75% in the proportion of
time on tamoxifen that overlapped with use of parox-
etine were associated with relative increases of 24%,
Table 1 |Characteristics by antidepressant group
Paroxetine
(n=630)
Fluoxetine
(n=253)
Sertraline
(n=541)
Fluvoxamine
(n=174)
Citalopram
(n=467)
Venlafaxine
(n=365)
Age (years)*
66-70 55 (8.7) 35 (13.8) 37(6.8) 10 (5.8) 32 (6.9) 49 (13.4)
71-75 159 (25.2) 79 (31.2) 119 (22.0) 34 (19.5) 118 (25.3) 153 (41.9)
76-80 181 (28.7) 68 (26.9) 153 (28.3) 51 (29.3) 125 (26.8) 83 (22.7)
81-85 124 (19.7) 49 (19.4) 110 (20.3) 42 (24.1) 106 (22.7) 51 (14.0)
≥86 111 (17.6) 22 (8.7) 122 (22.6) 37 (21.3) 86 (18.4) 29 (8.0)
Tamoxifen started†
≤365 days 517 (82.1) 184 (72.7) 439 (81.2) 142 (81.6) 412 (88.2) 331 (90.7)
>365 days 113 (17.9) 69 (27.3) 102 (18.9) 32 (18.4) 55 (11.8) 34 (9.3)
Drugs dispensed‡ 12 (8 to 16) 12 (8 to 16) 12 (8 to 15) 11 (7 to 17) 12 (8 to16) 10 (7 to15)
Income quintile§
1 (lowest) 130 (20.6) 58 (22.9) 106 (19.6) 35(20.1) 109 (23.3) 69 (18.9)
2 138 (21.9) 52 (20.6) 131 (24.2) 33 (19.0) 92 (19.7) 73 (20.0)
3 143 (22.7) 49 (19.4) 99 (18.3) 31 (17.8) 87(18.6) 69 (18.9)
4 111 (17.6) 43 (17.0) 93 (17.2) 38 (21.8) 86 (18.4) 81 (22.2)
5 (highest) 106 (16.8) 49 (19.4) 108 (20.0) 32 (18.4) 92 (19.7) 71(19.5)
Missing ** ** ** ** ** **
Year of diagnosis
1964-73 7 (1.1) ** ** ** ** **
1974-83 22 (3.5) 23 (9.1) 21 (3.9) ** 7 (1.5) **
1984-92 50 (7.9) 30 (11.9) 50 (9.2) 18 (10.3) 20 (4.3) 15 (4.1)
1993-2005 551 (87.5) 196 (77.5) 465 (86.0) 150 (86.2) 435 (93.2) 345 (94.5)
Tamoxifen duration 4.2 (2.3-5.0) 3.2 (1.4-4.8) 3.9 (2.1-4.9) 3.6 (1.7-5.0) 4.2 (2.5-5.1) 4.1 (2.5-4.9)
*Frequency (%) by age group in the year before stopping tamoxifen by antidepressant group.
†Frequency (%) starting tamoxifen within a year or greater from breast cancer diagnosis by antidepressant group.
‡Median number of drugs (IQR) dispensed in the year before completion of tamoxifen treatment by antidepressant group.
33
§Income quintiles used to estimate socioeconomic status by antidepressant group.
Median duration of tamoxifen use in years (IQR) by antidepressant group.
**Cell sizes ≤5 are suppressed in accordance with institutional privacy policy.
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respectively (table 2, fig 1). In contrast, we found no
increased risk of breast cancer mortality associated
with exposure to the other SSRIs during tamoxifen
treatment. We noted a non-significant trend towards
reduced breast cancer mortality among venlafaxine
users (table 2), which might reflect the common
practiceofusingvenlafaxinefor tamoxifen-relatedhot
flashes,
35 a potential predictor of better outcomes in
women receiving tamoxifen.
36
To test the robustness of our conclusions, we repli-
cated our analyses usingdeath from any cause (includ-
ing breast cancer) as the outcome of interest (n=1074).
After adjusting for potential confounders, we found
thatabsoluteincreasesof25%,50%,and75%inparox-
etine exposure during tamoxifen treatment were asso-
ciated with relative increases of 13%, 28% and 46%,
respectively,intheriskofdeathfromanycause(table3,
fig 2). By contrast, we found no such increased risk in
all-cause mortality associated with exposure to the
other SSRIs in women receiving tamoxifen for breast
cancer. Finally, we conducted an additional analysis
including 226 women whose cause of death was
unknown (total n=1300). This analysis again yielded
consistent results, showing an increased risk of death
only with paroxetine.
Estimate of absolute risks
To better characterise the absolute risks imparted by
use of paroxetine with tamoxifen, we generated abso-
lute risk estimates from our primary analysis using
methods described elsewhere
37 and applied
previously.
38 These estimates were obtained using a
Absolute proportion of tamoxifen treatment
characterised by antidepressant use
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Fig 1 | Risk of breast cancer mortality associated with
increasing proportions of antidepressant use during
tamoxifen treatment
Table 2 |Antidepressant exposure and risk of death from breast cancer in women receiving tamoxifen
Antidepressant
Deaths due to
breast cancer
Increase in proportion
of co-treatment* Unadjusted HR (95% CI) Adjusted HR (95% CI)†
Paroxetine (n=630) 105 –– –
– 0.25 1.17 (1.01 to 1.35) 1.24 (1.08 to 1.42)
– 0.50 1.36 (1.02 to 1.82) 1.54 (1.17 to 2.03)
– 0.75 1.59 (1.03 to 2.46) 1.91 (1.26 to 2.89)
Fluoxetine (n=253) 71 –– –
– 0.25 0.96 (0.81 to 1.13) 0.97 (0.82 to 1.15)
– 0.5 0.92 (0.66 to 1.27) 0.94 (0.67 to 1.32)
– 0.75 0.88 (0.54 to 1.43) 0.91 (0.55 to 1.51)
Sertaline (n=541) 115 –– –
– 0.25 0.96 (0.84 to 1.09) 1.00 (0.88 to 1.14)
– 0.5 0.92 (0.71 to 1.19) 1.00 (0.77 to 1.29)
– 0.75 0.88 (0.60 to 1.30) 0.99 (0.67 to 1.47)
Fluvoxamine (n=174) 38 –– –
– 0.25 1.04 (0.85 to 1.26) 0.98 (0.81 to 1.19)
– 0.5 1.08 (0.73 to 1.60) 0.96 (0.66 to 1.40)
– 0.75 1.12 (0.62 to 2.01) 0.94 (0.53 to 1.66)
Citalopram (n=467) 29 –– –
– 0.25 0.95 (0.71 to 1.26) 1.10 (0.82 to 1.47)
– 0.5 0.90 (0.51 to 1.59) 1.21 (0.68 to 2.16)
– 0.75 0.85 (0.36 to 2.01) 1.33 (0.56 to 3.17)
Venlafaxine (n=365) 16 –– –
– 0.25 0.61(0.37 to 0.99) 0.67 (0.41 to 1.09)
– 0.5 0.37(0.14 to 0.98) 0.45 (0.17 to 1.20)
– 0.75 0.22 (0.05 to 0.97) 0.30 (0.07 to 1.31)
*Absolute increases in proportion of time on tamoxifen treatment during which an antidepressant was co-prescribed.
†Adjusted for age in the year before stopping tamoxifen, year of starting tamoxifen, duration of tamoxifen treatment, timing of tamoxifen in relation to
date of breast cancer diagnosis (within one year of diagnosis or thereafter), socioeconomic status, comorbidity
33 in the year before stopping
tamoxifen, and receipt of other CYP2D6 inhibiting drugs (bupropion, quinidine, thioridazine, amiodarone, cimetidine or chloroquine) during tamoxifen
treatment.
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and their reciprocal is the number needed to treat to
harm (NNTh).
Compared with patients with minimal (1%) overlap
of paroxetine with tamoxifen, use of paroxetine for
41% of tamoxifen treatment (the median overlap in
our sample 8% to 80%) would result in one additional
breast cancer death at five years for every 19.7 (95%
confidence interval 12.5 to 46.3) women so treated.
Similarly, compared with patients with a 1% overlap,
we estimate that use of paroxetine for the entire dura-
tion of tamoxifen (100% overlap) would result in an
additionaldeathforevery6.9(95%confidenceinterval
4.3 to 18.6) patients so treated.
DISCUSSION
Usingpopulationbasedhealthcaredata,wefoundthat
women with breast cancer who received paroxetine in
combination with tamoxifen were at increased risk for
death from breast cancer and death from any cause.
The increased risk was directly related to the extent
of co-prescribing and is consistent with the hypothesis
thatirreversibleCYP2D6inhibitionbyparoxetinecan
reduce or abolish the survival advantage conferred by
long term tamoxifen therapy in patients with breast
cancer. We found no such risk with other anti-
depressants. Our findings are consistent with an
emerging body of literature indicating the critical role
ofCYP2D6inthemetabolicactivation
4515andclinical
effectiveness of tamoxifen.
9-14
Implications for clinical practice
Our findingshavemajor implications forclinical prac-
tice, particularly in light of the frequency of combina-
tion therapy. The prevalence of depression in women
Absolute proportion of tamoxifen treatment
characterised by antidepressant use
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Fig 2 | All-cause mortality associated with increasing
proportions of antidepressant use during tamoxifen therapy
Table 3 |Antidepressant exposure and risk of death from any cause in women receiving tamoxifen
Antidepressant
Deaths from any
cause
Proportion
of co-treatment* Unadjusted HR (95% CI) Adjusted HR (95% CI) †
Paroxetine (n=630) 296 –– –
– 0.25 1.12 (1.02 to 1.23) 1.13 (1.05 to 1.23)
– 0.5 1.25 (1.04 to 1.51) 1.28 (1.11 to 1.50)
– 0.75 1.40 (1.06 to 1.86) 1.46 (1.15 to 1.84)
Fluoxetine (n=253) 149 –– –
– 0.25 0.97 (0.86 to 1.10) 0.98 (0.89 to 1.09)
– 0.5 0.95 (0.75 to 1.20) 0.97 (0.79 to 1.19)
– 0.75 0.92 (0.64 to 1.32) 0.95 (0.70 to 1.29)
Sertraline (n=541) 321 –– –
– 0.25 1.02 (0.95 to 1.09) 1.06 (0.97 to 1.16)
– 0.5 1.04 (0.90 to 1.19) 1.12 (0.94 to 1.34)
– 0.75 1.05 (0.86 to 1.30) 1.19 (0.91 to 1.56)
Fluvoxamine (n=174) 112 –– –
– 0.25 1.05 (0.93 to 1.18) 1.00 (0.89 to 1.12)
– 0.5 1.09 (0.86 to 1.39) 1.00 (0.80 to 1.26)
– 0.75 1.15 (0.80 to 1.64) 1.00 (0.71 to 1.41)
Citalopram (n=467) 135 –– –
– 0.25 0.98 (0.86 to 1.12) 1.07 (0.92 to 1.23)
– 0.5 0.96 (0.74 to 1.25) 1.14 (0.85 to 1.51)
– 0.75 0.94 (0.64 to 1.40) 1.21 (0.79 to 1.86)
Venlafaxine (n=365) 61 –– –
– 0.25 0.96 (0.80 to 1.15) 1.04 (0.87 to 1.24)
– 0.5 0.92 (0.64 to 1.33) 1.08 (0.76 to 1.54)
– 0.75 0.89 (0.51 to 1.54) 1.13 (0.66 to 1.92)
*Absolute increases the proportion of time on tamoxifen treatment during which antidepressant was co-prescribed.
†Adjusted for age in the year before stopping tamoxifen, year of starting tamoxifen, duration of tamoxifen treatment, timing of tamoxifen in relation to
date of breast cancer diagnosis (within one year of diagnosis or thereafter), socioeconomic status, comorbidity
33 in the year before stopping
tamoxifen, and receipt of other CYP2D6 inhibiting drugs (bupropion, quinidine, thioridazine, amiodarone, cimetidine or chloroquine) during tamoxifen
treatment.
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general female population and is particularly high
around the time of diagnosis.
39 In our study, 30% of
womenwhostartedtamoxifentreatmentalso received
antidepressants, and paroxetine was the most com-
monly used SSRI. These patients may also take
SSRIs for other indications; up to 80% of women trea-
ted with tamoxifen experience hot flashes,
40 and clini-
cal trials have shown the efficacy of SSRIs for their
treatment.
20
Strengths of the study
Our findings differ from previous research reporting
no significant association between SSRI treatment
and adverse outcome in women receiving tamoxifen.
Insufficient statistical power, use of a case control
design, and assessment of a single SSRI with weak
CYP2D6-inhibiting activity
1841-43 might have ham-
pered the ability of these studies to detect clinically
important differences in outcome. In the context of
drug interactions, case control studies are better suited
to the study of short term risks resulting from drug
interactions rather than long term risks.
2529303244
Limitations of the study
Some limitations of our study merit emphasis. We
could not ascertain the indication for antidepressant
treatment, but our finding of an increased mortality
risk with paroxetine has strong biological plausibility
and is not readily explained by selection bias. Some
women taking tamoxifen may have been prescribed
newer antidepressants for treatment of tamoxifen
related hot flashes,
20 which have been associated with
better response to treatment.
36 These observations
may underlie the trend towards lower breast cancer
mortality observed with venlafaxine, which exhibits
minimal CYP2D6 inhibition and is commonly used
for hot flashes.
45-47 Although other SSRIs may also be
used for hot flashes, confounding by indication is an
unlikely explanation for our remaining observations,
as this would tend to result in negative associations
between increasing drug overlap and breast cancer
mortality.
Wedidnothaveinformationonbreastcancerstage,
whichisanimportantpredictorofoutcome.However,
because we conducted a within-SSRI analysis, this is
unlikely to bias our findings. There is no reason why
women with more advanced breast cancer should be
preferentially prescribed paroxetine rather than other
antidepressants.Wecannotexcludethepossibilitythat
individuals who received longer durations of paroxe-
tine while taking tamoxifen had more severe disease,
although this seems clinically implausible.
2148
About 7% of individuals exhibit no functional
CYP2D6activity
7and are thereforeunable to convert
tamoxifen to endoxifen. These individuals may have
fewer tamoxifen associated hot flashes, and may have
betteradherencetotamoxifenbutapoorerresponseto
the drug.
49 Although we do not have genotype infor-
mation on our study participants, the inclusion in our
analysis of patients with loss-of-function poly-
morphisms will tend to minimise the clinical conse-
quences of drug induced CYP2D6 inhibition, and can
onlyattenuatetheabilityofouranalysistodiscriminate
among SSRIs.
The finding of an increased risk of death from any
cause in women co-prescribed paroxetine has at least
twocontributing explanations. First,breastcancerwas
the mostcommon cause of death in thesepatients,and
an association between paroxetine use and total mor-
talitywasthereforeexpected.Second,somedeathsnot
specifically ascribed to breast cancer might have
reflectedremoteeffectsofthedisease(suchaspulmon-
ary embolism or cardiac tamponade) or the disease
itself, particularly when no other cause of death was
recorded. Importantly, these limitations apply to all
antidepressants, and cannot explain the differential
mortality risk observed with paroxetine treatment.
Although the degree to which various SSRIs inhibit
CYP2D6differsamongstudies,thereisconsensusthat
bothfluoxetineanditsmetabolitearestronginhibitors
of CYP2D6.
5051 However, we found no association
between increasing use of fluoxetine and death from
breast cancer among women taking tamoxifen. The
reasons for this are unclear, but might reflect the rela-
tivelysmallnumberofwomenexposedtofluoxetinein
our study sample. Our results should not be viewed as
evidencethatfluoxetinecanbesafelyusedincombina-
tion with tamoxifen. Similarly, we cannot exclude the
possibility that insufficient sample size explains the
non-significant mortality results with other SSRIs.
Conclusion
In conclusion, our findings indicate that the choice of
antidepressant can significantly affect survival in
women receiving tamoxifen for breast cancer. This
observation is consistent with the critical role of
CYP2D6 in the metabolic activation of tamoxifen,
andhighlightsadruginteractionthatisextremelycom-
mon, widely underappreciated and uniformly avoid-
able. Tamoxifen is a crucial element of treatment for
patients with hormone receptor positive breast cancer
regardless of age or breast cancer stage. When co-pre-
scription of tamoxifen with an antidepressant is
WHAT IS ALREADY KNOWN ON THIS TOPIC
Tamoxifen is important in the endocrine treatment of breast cancer and is a prodrug
converted by cytochrome P450 2D6 (CYP2D6) to its active metabolite endoxifen.
Selective serotonin inhibitor (SSRI) antidepressants are widely prescribed to women with
breast cancer taking tamoxifen, but inhibit CYP2D6 to varying degrees and may affect
tamoxifen’s effectiveness.
WHAT THIS STUDY ADDS
Use of paroxetine (a potent, irreversible CYP2D6 inhibitor) during tamoxifen treatment is
associated with an increased subsequent risk of death due to breast cancer in a fashion that
correlates with the duration of combined use.
We estimate that treatment with paroxetine for 41% of tamoxifen therapy (the median in our
study) could result in one additional breast cancer death at five years for every 20 women so
treated.
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depressants that show little or no inhibition of
CYP2D6.
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